FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

The FDA approved a supplemental application for NEULASTA (pegfilgrastim) from Amgen, Inc. The approval updates the labeling related to its indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Chemotherapy-induced Neutropenia
• Neutropenia

Drugs mentioned

• NEULASTA (pegfilgrastim)

Snippet

SUPPL AP for NEULASTA (PEGFILGRASTIM)